DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Table 25–5
Inhibitors of Na + -Cl – Symport (Thiazide and Thiazide-like Diuretics)
RELATIVE ORAL t 1/2
ROUTE OF
DRUG STRUCTURE POTENCY AVAILABILITY (HOURS) ELIMINATION
Bendroflumethiazide 10 ~100% 3–3.9 ~30% R,
(NATURETIN)
R 2 3 CH 2 , R 6 CF 3
~70% M
Chlorothiazide 0.1 9–56% (dose- ~1.5 R
(DIURIL) (Unsaturated between C3 and N4) dependent)
Hydrochlorothiazide 1 ~70% ~2.5 R
(HYDRODIURIL)
Hydroflumethiazide 1 ~50% ~17 40-80% R,
(SALURON)
20-60% M
Methyclothiazide 10 ID ID M
(ENDURON)
Polythiazide R 2 CH 3 , R 3 CH 2 SCH 2 CF 3 , R 6 Cl 25 ~100% ~25 ~25% R,
(RENESE)
~75% U
Trichlormethiazide 25 ID 2.3-7.3 R
(NAQUA)
Chlorthalidone OH
1 ~65% ~47 ~65% R,
SO
(HYGROTON) 2 NH 2
~10% B,
NH
CI
~25% U
O
Indapamide (LOZOL) H 3 C
20 ~93% ~14 M
CI
C
N
N
H 2 NO 2 S
O
H
Metolazone H
10 ~65% ID ~80% R,
(MYKROX, CH 3
~10% B,
CI N
ZAROXOLYN)
H
~10% M
H 2 NO 2 S
N
O
H 3 C
Quinethazone H
1 ID ID ID
(HYDROMOX)
CI N CH 2 CH 3
H 2 NO 2 S
O
NH
Abbreviations: R, renal excretion of intact drug; M, metabolism; B, excretion of intact drug into bile; U, unknown pathway of elimination; ID,
insufficient data.